Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network

Cancer

Volumn 119, Issue 4, 2013, Pages 839-846

  Freedman, Rachel A ^a   Hughes, Melissa E ^a   Ottesen, Rebecca A ^b   Weeks, Jane C ^a   He, Yulei ^c   Wong, Yu Ning ^d   Theriault, Richard ^e   Keating, Nancy L ^c,f  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Division of Biostatistics   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

breast cancer; disparities; race; socioeconomic status; trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADJUVANT THERAPY; AFRICAN AMERICAN; ARTICLE; ASIAN; BREAST CANCER; CANCER CENTER; CANCER STAGING; CAUCASIAN; COHORT ANALYSIS; DATA BASE; EDUCATIONAL STATUS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; ETHNICITY; FEMALE; HEALTH CARE DISPARITY; HISPANIC; HUMAN; HUMAN ESTROGEN RECEPTOR 2 POSITIVE BREAST CANCER; MAJOR CLINICAL STUDY; NATIONAL COMPREHENSIVE CANCER NETWORK BREAST CANCER OUTCOME DATABASE; PACIFIC ISLANDER; PATIENT EDUCATION; PRIORITY JOURNAL; SOCIAL STATUS; TREATMENT DURATION; UNITED STATES;

AFRICAN AMERICANS; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; EDUCATIONAL STATUS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; UNITED STATES;

EID: 84873407216     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27831     Document Type: Article

References (39)

1. Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003; 421: 756-760.
2. Yarden Y,. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001; 37 (suppl 4): S3-S8.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL,. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177-182.
4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version I. 2012. Available at: http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf/. Accessed March 13, 2012.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353: 1659-1672.
6. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353: 1673-1684.
7. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365: 1273-1283.
8. Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM,. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007; 25: 634-641.
9. Bickell NA, Wang JJ, Oluwole S, et al. Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol. 2006; 24: 1357-1362.
10. Freedman RA, He Y, Winer EP, Keating NL,. Trends in racial and age disparities in definitive local therapy of early stage breast cancer. J Clin Oncol. 2009; 27: 713-719.
11. Lund MJ, Brawley OP, Ward KC, Young JL, Gabram SS, Eley JW,. Parity and disparity in first course treatment of invasive breast cancer. Breast Cancer Res Treat. 2007; 109: 545-557.
12. Shavers VL, Harlan LC, Stevens JL,. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer. 2003; 97: 134-147.
13. Jatoi I, Anderson WF, Rao SR, Devesa SS,. Breast cancer trends among black and white women in the United States. J Clin Oncol. 2005; 23: 7836-7841.
14. Wu XC, Lund MJ, Kimmick GG, et al. Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol. 2012; 30: 142-150.
15. Griggs JJ, Culakova E, Sorbero ME, et al. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol. 2007; 25: 2522-2527.
16. Bradley CJ, Given CW, Roberts C,. Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst. 2002; 94: 490-496.
17. Bhargava A, Du XL,. Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer. Cancer. 2009; 115: 2999-3008.
18. Sprague BL, Trentham-Dietz A, Gangnon RE, et al. Socioeconomic status and survival after an invasive breast cancer diagnosis. Cancer. 2011; 117: 1542-1551.
19. National Comprehensive Cancer Network (NCCN). NCCN Oncology Outcomes Database Project. Available at: http://www.nccn.org/network/business-insights/ outcomes-database/outcomes.asp. Accessed July 10, 2011.
20. Weeks JC,. Outcomes assessment in the NCCN. Oncology (Williston Park). 1997; 11 (11A): 137-140.
21. Weeks J,. Outcomes assessment in the NCCN: 1998 update. National Comprehensive Cancer Network. Oncology (Williston Park). 1999; 13 (5A): 69-71.
22. Niland JC,. NCCN outcomes research database: data collection via the internet. Oncology (Williston Park). 2000; 14 (11A): 100-103.
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
24. Katz JN, Chang LC, Sangha O, Fossel AH, Bates DW,. Can comorbidity be measured by questionnaire rather than medical record review? Med Care. 1996; 34: 73-84.
25. Dobie SA, Baldwin LM, Dominitz JA, Matthews B, Billingsley K, Barlow W,. Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst. 2006; 98: 610-619.
26. Gibbs P, McLaughlin S, Skinner I, et al. Re: completion of therapy by Medicare patients with stage III colon cancer [letter]. J Natl Cancer Inst. 2006; 98: 1582.
27. Neugut AI, Matasar M, Wang X, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol. 2006; 24: 2368-2375.
28. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006; 354: 809-820.
29. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE,. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol. 1997; 15: 1544-1552.
30. Hasan S, Dinh K, Lombardo F, Kark J,. Doxorubicin cardiotoxicity in African Americans. J Natl Med Assoc. 2004; 96: 196-199.
31. Grenier MA, Lipshultz SE,. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol. 1998; 25 (4 suppl 10): 72-85.
32. Snider JN, Ahmed S, Paba C, et al. cardiotoxicity of trastuzumab treatment in African American women and older women in the nontrial setting [abstract]. Paper presented at: 32nd Annual San Antonio Breast Cancer Symposium; December 1-13, 2009; San Antonio, TX. Abstract 5087.
33. Partridge AH, Wang PS, Winer EP, Avorn J,. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003; 21: 602-606.
34. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early stage breast cancer patients. J Clin Oncol. 2010; 28: 4120-4128.
35. Hedin T, Guo C, Nattinger A,. Persistence with adjuvant hormone therapy in older breast cancer survivors [abstract]. J Clin Oncol. 2011; 29S. Abstract 6032.
36. Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS,. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006; 24: 2750-2756.
37. Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS,. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol. 2006; 24: 2757-2764.
38. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002; 20: 1215-1221.
39. Serrano C, Cortes J, De Mattos-Arruda L, et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol. 2011; 23: 897-902.